It's about having enough data to fit the FDA's gui
Post# of 148297
(Total Views: 377)
Posted On: 02/23/2020 2:51:47 PM
Re: crazyjogger925 #19123
It's about having enough data to fit the FDA's guidelines.
The struggle with cancer indications is likely going to be having data that's comprehensive enough.
In my experience the best rule to remember is that everything takes longer than expected (obviously the BLA is a prime example).
The struggle with cancer indications is likely going to be having data that's comprehensive enough.
In my experience the best rule to remember is that everything takes longer than expected (obviously the BLA is a prime example).
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼